Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 2/20 | 0.58 |
| ▸ | GRM8 | O00222 | 1/20 | 0.58 |
| ▸ | GRM6 | O15303 | 1/20 | 0.58 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.58 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.58 |
| ▸ | GSR | P00390 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.58 |
| ▸ | GRM5 | P41594 | 1/20 | 0.58 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.58 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.58 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.58 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.58 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.58 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.58 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.58 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.58 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.58 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL338792 | 1.00 | SLC1A1 (0.58) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL6146852 | 1.00 | SLC1A1 (0.58) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL27805447 | 0.98 | SLC1A1 (0.56) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL3174569 | 0.98 | SLC1A1 (0.56) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL7445184 | 0.98 | SLC1A1 (0.56) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| Glutamic Acid SCHEMBL1930763 | 0.94 | SLC1A1 (0.69) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| Sulfuric Acid SCHEMBL28734792 | 0.92 | SLC1A1 (0.50) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| Phosphoric Acid SCHEMBL28734817 | 0.92 | GRM8 (0.50) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL21268583 | 0.91 | SLC1A1 (0.48) | SLC1A1GRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL23030218 | 0.88 | ENPEP (0.47) | SLC1A1GRM8GRM6GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 437 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119470406-A | Phthalic dicarboxaldehyde disinfectant concentration detection test paper and preparation method thereof | 山东新华莎罗雅生物技术有限公司 | 2025-02-18 | — | — | CN | claimed |
| US-20240261422-A1 | ANTHRACYCLINE ANTIBODY CONJUGATES | SEAGEN INC (US) | 2024-08-08 | — | — | US | claimed |
| US-20240123079-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | SEAGEN INC. | 2024-04-18 | — | — | US | claimed |
| EP-4346906-A1 | ANTHRACYCLINE ANTIBODY CONJUGATES | Seagen Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| US-11905527-B2 | Gel composition for culturing cells, production method thereof, method for culturing cells, and substrate for culturing cells | SHIMADZU CORPORATION (JP) | 2024-02-20 | — | — | US | claimed |
| CN-117580593-A | Anthracycline antibody conjugates | 思进公司 | 2024-02-20 | — | — | CN | claimed |
| CN-115611964-B | Ursolic acid saponin with inflammatory bowel disease treatment effect, derivative thereof, preparation method and application | 沈阳药科大学 | 2024-02-06 | — | — | CN | claimed |
| EP-4277904-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | Seagen Inc. (US) | 2023-11-22 | — | — | EP | claimed |
| CN-116829551-A | Immunomodulatory antibody drug conjugates | 思进公司 | 2023-09-29 | — | — | CN | claimed |
| CN-115611964-A | Ursolic acid saponin with inflammatory bowel disease treatment effect, derivatives thereof, preparation method and application | 沈阳药科大学 | 2023-01-17 | — | — | CN | claimed |
| CN-1468095-A | Colloidal suspension of submicronic particles for carrying hydrophilic active principles (insulin) and method for preparing same | ÷ | 2004-01-14 | — | — | CN | claimed |
| CN-1468144-A | Colloidal suspension of submicronic particles for carrying active principles and their mode of preparation | ÷ | 2004-01-14 | — | — | CN | claimed |
| CN-1413270-A | Chemical cleaning solution for gas turbine blades | BIOGENESIS ENTPR INC (US) | 2003-04-23 | — | — | CN | claimed |
| US-6329502-B1 | VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS; TREATMENT OF AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) | JAPAN ENERGY CORPORATION (JP) | 2001-12-11 | — | — | US | claimed |
| US-6313094-B1 | COMPOSITION FOR INHIBITING HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | JAPAN ENERGY CORPORATION (JP) | 2001-11-06 | — | — | US | claimed |
| JP-3098772-B2 | — | — | 2000-10-16 | — | — | JP | claimed |
| US-5676936-A | INCORPORATING A COMPOUND HAVING A BASIC NITROGEN FUNCTION OR A BASIC OXYGEN FUNCTION | CHESEBROUGH-POND'S U.S.A. CO. (US) | 1997-10-14 | — | — | US | claimed |
| US-5518714-A | ADDITION OF BASIC COMPOUND SUCH AS AMINE, AMINO ACID, HYDROXIDE, OXIDE, CARBONATE | CHESEBROUGH-POND'S USA CO., DIVISION OF CONOPCO, INC. (US) | 1996-05-21 | — | — | US | claimed |
| EP-0527851-A1 | 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1993-02-24 | — | — | EP | claimed |
| WO-1991017148-A1 | 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1991-11-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240123079-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | CD47, CD22, FCGR2A | SLC1A1 1511/4885GRM8 832/4885GRM6 465/4885 |
| US-20240261422-A1 | ANTHRACYCLINE ANTIBODY CONJUGATES | BCR, TOP2A, ABCB1 | SLC1A1 1034/4885GRM8 4387/4885GRM6 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.